Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

MMPIs inhibitors

BMS-275291 is the first compound in clinical development from this new generation of MMPIs. BMS-275291 is a sulfhydryl-based broad-spectrum MMP inhibitor that is rationally designed to be less active toward the sheddases. Its chemical structure is shown in Fig. 1. [Pg.383]

Hurwitz H, Humphrey J, Williams K, Ness E, Conway A, Bielefield M, et al. A phase I trial of BMS-275291 a novel, non-hydroxamate, sheddase-sparing matrix metalloproteinase inhibitor (MMPI) with no dose-limiting arthritis. Proc Anna Meet Am Soc Clin Oncol 2001 (abstract) submitted. [Pg.390]

Pavlaki, M., and Zucker, S., Matrix metalloproteinase inhibitors (MMPIs) The beginning of phase 1 or the termination of phase IB clinical trials. Cancer Metastasis Reviews 22, 177-203 (2003). [Pg.82]

Matrix metalloproteinase inhibitors (MMPIs) from marine natural products the current situation and future prospect. Zhang, G., Kim, S.-K. (2009) Mar. Drugs, 7, 71-84. [Pg.69]

See other pages where MMPIs inhibitors is mentioned: [Pg.228]    [Pg.379]    [Pg.381]    [Pg.383]    [Pg.383]    [Pg.92]    [Pg.223]    [Pg.327]    [Pg.83]    [Pg.126]    [Pg.127]    [Pg.343]    [Pg.130]    [Pg.191]   


SEARCH



MMPIs

Matrix metalloproteinase inhibitors MMPIs)

© 2024 chempedia.info